NCT06468943View on ClinicalTrials.gov

Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2028

Conditions
Effects of ChemotherapySafety Issues
Interventions
DRUG

Polatuzumab Vedotin

1.8mg/kg/21d（d0） Intravenous infusion

DRUG

Zanubrutinib

160mg bid PO（d0-d20）

DRUG

Rituximab

375mg/㎡/21d（d0） Intravenous infusion

DRUG

Cyclophosphamide

750mg/㎡/21d（d1） Intravenous infusion

DRUG

Doxorubicin

50mg/㎡/21d（d1） Intravenous infusion

DRUG

Prednisone

100mg PO （d1-d5）/21d

Trial Locations (1)

215000

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER